Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Gemcitabine HCL Market: By Type: Branded, Generic; By Application: Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small-Cell Lung Carcinoma (NSCLC), Others; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Gemcitabine HCL Market Outlook
The global gemcitabine HCL market is projected to grow at a CAGR of 6.5% during the forecast period of 2022-2027. With the rise in demand for chemotherapy to treat various kinds of cancer, including breast cancer, ovarian cancer, and non-small cell lung cancer, the gemcitabine HCL market is witnessing a significant growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
Gemcitabine HCL can be used alone or with a combination of other drugs to treat cancers like breast cancer, non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global gemcitabine HCL market can be segmented based on types, applications, end-uses, and regions.
Based on its types, the industry can be categorised as branded and generic.
Based on its application, the gemcitabine HCL market can be segmented into:
- Pancreatic Cancer
- Breast Cancer
- Ovarian Cancer
- Non-Small-Cell Lung Carcinoma (NSCLC)
- Others
Based on its end-uses, the industry can be segmented as hospitals and cancer centres, among others.
The EMR report looks into the regional gemcitabine HCL markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
This increase in the number of cancer cases, along with the rising geriatric population and the associated risk factors, is driving the industry for gemcitabine HCL. Further, with the rise in the number of governmental and healthcare patient support organisations and agencies, which are spreading awareness regarding cancer, the industry is expected to receive a further boost. Technical advancements in the production of generic drugs have led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market over the forecast period.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global gemcitabine HCL market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Eli Lilly and Company (NYSE: LLY)
- Teva Pharmaceutical Industries Ltd.
- Accord Healthcare Ltd.
- Pfizer, Inc.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Dr. Reddy’s Laboratories Ltd.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Application, End Use, Region |
| Breakup by Type | Branded, Generic |
| Breakup by Application | Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-Small-Cell Lung Carcinoma (NSCLC), Others |
| Breakup by End Use | Hospitals, Cancer Centres, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Price Analysis | Historical and Forecast Price Trends- Regional |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Eli Lilly and Company (NYSE: LLY), Teva Pharmaceutical Industries Ltd. (TLV: TEVA), Accord Healthcare Ltd., Pfizer, Inc. (NYSE: PFE), Mylan N.V. (NASDAQ: MYL), Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA), Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY), Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Gemcitabine HCL Market Analysis
8.1 Key Industry Highlights
8.2 Global Gemcitabine HCL Historical Market (2017-2021)
8.3 Global Gemcitabine HCL Market Forecast (2022-2027)
8.4 Global Gemcitabine HCL Market by Type
8.4.1 Branded
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Generic
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.5 Global Gemcitabine HCL Market by Application
8.5.1 Pancreatic Cancer
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Breast Cancer
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Ovarian Cancer
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Non-Small-Cell Lung Carcinoma (NSCLC)
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.5.5 Others
8.6 Global Gemcitabine HCL Market by End Use
8.6.1 Hospitals
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Cancer Centres
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Others
8.7 Global Gemcitabine HCL Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Company Profiles
13.2.1 Eli Lilly and Company
13.2.1.1 Company Overview
13.2.1.2 Product Portfolio
13.2.1.3 Demographic Reach and Achievements
13.2.1.4 Certifications
13.2.2 Teva Pharmaceutical Industries Ltd
13.2.2.1 Company Overview
13.2.2.2 Product Portfolio
13.2.2.3 Demographic Reach and Achievements
13.2.2.4 Certifications
13.2.3 Accord Healthcare Ltd.
13.2.3.1 Company Overview
13.2.3.2 Product Portfolio
13.2.3.3 Demographic Reach and Achievements
13.2.3.4 Certifications
13.2.4 Pfizer Inc.
13.2.4.1 Company Overview
13.2.4.2 Product Portfolio
13.2.4.3 Demographic Reach and Achievements
13.2.4.4 Certifications
13.2.5 Mylan N.V.
13.2.5.1 Company Overview
13.2.5.2 Product Portfolio
13.2.5.3 Demographic Reach and Achievements
13.2.5.4 Certifications
13.2.6 Fresenius Kabi AG
13.2.6.1 Company Overview
13.2.6.2 Product Portfolio
13.2.6.3 Demographic Reach and Achievements
13.2.6.4 Certifications
13.2.7 Sun Pharmaceutical Industries Ltd.
13.2.7.1 Company Overview
13.2.7.2 Product Portfolio
13.2.7.3 Demographic Reach and Achievements
13.2.7.4 Certifications
13.2.8 Dr. Reddy’s Laboratories Ltd.
13.2.8.1 Company Overview
13.2.8.2 Product Portfolio
13.2.8.3 Demographic Reach and Achievements
13.2.8.4 Certifications
13.2.9 Others
14 Industry Events and Developments
List of Key Figures and Tables
1. Global Gemcitabine HCL Market: Key Industry Highlights, 2017 and 2027
2. Global Gemcitabine HCL Historical Market: Breakup by Type (USD Billion), 2017-2021
3. Global Gemcitabine HCL Market Forecast: Breakup by Type (USD Billion), 2022-2027
4. Global Gemcitabine HCL Historical Market: Breakup by Application (USD Billion), 2017-2021
5. Global Gemcitabine HCL Market Forecast: Breakup by Application (USD Billion), 2022-2027
6. Global Gemcitabine HCL Historical Market: Breakup by End Use (USD Billion), 2017-2021
7. Global Gemcitabine HCL Market Forecast: Breakup by End Use (USD Billion), 2022-2027
8. Global Gemcitabine HCL Historical Market: Breakup by Region (USD Billion), 2017-2021
9. Global Gemcitabine HCL Market Forecast: Breakup by Region (USD Billion), 2022-2027
10. North America Gemcitabine HCL Historical Market: Breakup by Country (USD Billion), 2017-2021
11. North America Gemcitabine HCL Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Europe Gemcitabine HCL Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Europe Gemcitabine HCL Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Asia Pacific Gemcitabine HCL Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Asia Pacific Gemcitabine HCL Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Latin America Gemcitabine HCL Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Latin America Gemcitabine HCL Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Middle East and Africa Gemcitabine HCL Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Middle East and Africa Gemcitabine HCL Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Global Gemcitabine HCL Market Structure
Key Questions Answered in the Report
The global gemcitabine HCL market is projected to grow at a CAGR of 6.5% between 2021 and 2026.
The major drivers of the industry, such as the growing prevalence of cancer and other diseases, rising disposable incomes, increasing population, growing demand for generic drugs, increased government initiatives to create health awareness, growing geriatric population, and rapid advancement in the field of medicine and science, are expected to aid the market growth.
The key market trends guiding the growth of the market include the growing investment in the research and development of drugs and growth in the number of clinical trials being conducted across the globe.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Branded and generic are the major gemcitabine HCL types in the industry.
The significant applications of the product are pancreatic cancer, breast cancer, ovarian cancer, and non-small-cell lung carcinoma (NSCLC), among others.
Hospitals and cancer centres, among others, are the major end use sectors of the product.
The major players in the industry are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, and Dr. Reddy’s Laboratories Ltd., among others.
Analyst Review
The global gemcitabine HCL market is being driven by the rising cases of cancer and growth in the sales of generic drugs. Aided by the growing number of clinical trials, the market is expected to witness a healthy growth in the forecast period of 2022-2027, growing at a CAGR of 6.5%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on types, the gemcitabine HCL industry can be bifurcated into branded and generic. On the basis of applications, the industry is divided into pancreatic cancer, breast cancer, ovarian cancer, and non-small-cell lung carcinoma (NSCLC), among others. On the basis of end use, the industry is segregated into hospitals, and cancer centres, among others. The major regional markets for gemcitabine HCL are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, and Dr. Reddy’s Laboratories Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER